Anagliptin vs Retagliptin/metformin (Ruilintang)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Anagliptin · Suiny
Marketed by Sanwa Kagaku Kenkyusho and partners
NCT01529541 · Phase 3 · completed
The study randomly assigned an estimated 200 participants and used triple masking with sitagliptin as an active comparator. Its primary endpoint was the change in HbA1c, a surrogate measure, and no primary-outcome result is available to show whether the comparison was favorable.
Next expected readout: March 2027 · NCT07442006 (registry estimate)
Reported efficacy
The Change in HbA1c from baseline to week24 (0wk, 8wk, 16wk, 24wk): HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo. (met)
Result source: NCT01529528
Retagliptin/metformin (Ruilintang)
Marketed by Jiangsu Hengrui Pharmaceuticals
NCT05415644 · Phase 1 · completed
This is a randomized, blinded, crossover comparison against the reference formulation, which is a sound design for its purpose, but it measures only drug levels in the blood rather than a diabetes outcome, and no results have been posted yet.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Anagliptin | Retagliptin/metformin (Ruilintang) |
|---|---|---|
| HbA1c, change | -0.5% vs 0.2%a−0.7 vs placeboNCT015295282 other results
| —Not reported |
| Body weight, change (kg) | —Not posted · NCT01529528 | —Not reported |
| HbA1c below 7% | —Not posted · NCT01529528 | —Not reported |
| Fasting plasma glucose, change | —Not posted · NCT01529528 | —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT01529528 | —Not reported |
HbA1c, change
- Anagliptin
- -0.5% vs 0.2%a−0.7 vs placeboNCT01529528
2 other results
- -0.5% vs 0.2% NCT01529528
- -0.8% vs -0.8% NCT01529541
- Retagliptin/metformin (Ruilintang)
- —Not reported
Body weight, change (kg)
- Anagliptin
- —Not posted · NCT01529528
- Retagliptin/metformin (Ruilintang)
- —Not reported
HbA1c below 7%
- Anagliptin
- —Not posted · NCT01529528
- Retagliptin/metformin (Ruilintang)
- —Not reported
Fasting plasma glucose, change
- Anagliptin
- —Not posted · NCT01529528
- Retagliptin/metformin (Ruilintang)
- —Not reported
3-point MACE (% with event)
- Anagliptin
- —Not posted · NCT01529528
- Retagliptin/metformin (Ruilintang)
- —Not reported
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Retagliptin/metformin (Ruilintang): no structured comparison results are available for Type 2 Diabetes.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Anagliptin
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anagliptin's landscape · Retagliptin/metformin (Ruilintang)'s landscape